Prevention of cytomegalovirus infection in organ transplant recipients

Editorial

R H Rubin. Transpl Infect Dis. 2000 Sep.

. 2000 Sep;2(3):99-100.

doi: 10.1034/j.1399-3062.2000.020301.x.

No abstract available

Comment on

Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
Rubin RH, Kemmerly SA, Conti D, Doran M, Murray BM, Neylan JF, Pappas C, Pitts D, Avery R, Pavlakis M, Del Busto R, DeNofrio D, Blumberg EA, Schoenfeld DA, Donohue T, Fisher SA, Fishman JA. Rubin RH, et al. Transpl Infect Dis. 2000 Sep;2(3):112-7. Transpl Infect Dis. 2000. PMID: 11429021 Clinical Trial.
Preemptive treatment approach to cytomegalovirus (CMV) infection in solid organ transplant patients: relationship between compliance with the guidelines and prevention of CMV morbidity.
Künzle N, Petignat C, Francioli P, Vogel G, Seydoux C, Corpataux JM, Sahli R, Meylan PR. Künzle N, et al. Transpl Infect Dis. 2000 Sep;2(3):118-26. doi: 10.1034/j.1399-3062.2000.020304.x. Transpl Infect Dis. 2000. PMID: 11429022